Regenxbio Inc(RGNX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RGNX Regenxbio Inc

已收盘 09-10 16:00:00 EDT

8.56

-0.17

-1.95%

盘后8.56

+0.000.00%

19:30 EDT

最高8.79	最低8.47	成交量117.21万
今开8.63	昨收8.73	日振幅3.67%
总市值5.65亿	流通市值4.91亿	总股本6,601万
成交额1,005万	换手率2.04%	流通股本5,734万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RGNX","market":"US","secType":"STK","nameCN":"Regenxbio Inc","latestPrice":8.56,"timestamp":1789070400000,"preClose":8.73,"halted":0,"volume":1172065,"hourTrading":{"tag":"盘后","latestPrice":8.56,"preClose":8.56,"latestTime":"19:30 EDT","volume":189457,"amount":1621752.3606,"timestamp":1789083006943,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01947308132875142,"floatShares":57342700,"shares":66013200,"eps":-3.765189,"marketStatus":"已收盘","change":-0.17,"latestTime":"09-10 16:00:00 EDT","open":8.63,"high":8.79,"low":8.47,"amount":10046535.645510001,"amplitude":0.036655,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.765189,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1442462400000,"exchange":"NASDAQ","adjPreClose":8.73,"preHourTrading":{"tag":"盘前","latestPrice":8.63,"preClose":8.73,"latestTime":"09:29 EDT","volume":1830,"amount":15803.693339999998,"timestamp":1789046999999,"change":-0.1,"changeRate":-0.011455,"amplitude":0.036655},"postHourTrading":{"tag":"盘后","latestPrice":8.56,"preClose":8.56,"latestTime":"19:30 EDT","volume":189457,"amount":1621752.3606,"timestamp":1789083006943,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.130768,"impliedVol":1.6189,"impliedVolPercentile":0.8964},"requestUrl":"/m/hq/s/RGNX/tweets","defaultTab":"tweets","newsList":[{"id":"1131206249","title":"FDA叫停Regenxbio亨特综合征基因疗法临床试验，盘前股价暴跌25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131206249","media":"美股速递","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131206249?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:44","pubTimestamp":1787571849,"startTime":"0","endTime":"0","summary":"Regenxbio公司股价在盘前交易时段重挫25%，起因是美国食品药品监督管理局对其用于治疗亨特综合征的基因疗法项目下达了临床试验暂停令。该公司针对亨特综合征的基因治疗药物，原本被视为其研发管线中的明星产品，承载着无数患者与股东的殷切期望。截至目前，Regenxbio官方尚未就FDA作出该决定的具体原因发布详细声明，也未披露临床暂停所涉及的具体细节。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNX","BK4505","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120715731","title":"Regenxbio在视网膜专家协会年会上公布Surabgene Lomparvovec治疗湿性AMD及糖尿病视网膜病变的积极长期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1120715731","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120715731?lang=zh_cn&edition=full","pubTime":"2026-07-19 03:17","pubTimestamp":1784402232,"startTime":"0","endTime":"0","summary":"Regenxbio Inc于美国视网膜专家协会年度会议上，公布了其基因疗法Surabgene Lomparvovec在治疗湿性年龄相关性黄斑变性及糖尿病视网膜病变方面的积极长期随访数据。该数据展示了该疗法在延长疗效持续时间、改善患者视力预后以及维持良好安全性方面的潜力，为这类视网膜血管疾病患者提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","RGNX","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179995011","title":"Regenxbio Inc预计7月召开A类会议 并计划会后于2026年第三季度迅速重新提交BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=1179995011","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179995011?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:40","pubTimestamp":1782128441,"startTime":"0","endTime":"0","summary":"Regenxbio Inc 近日表示，公司预计将在今年7月与美国食品药品监督管理局（FDA）举行一次A类会议。此次会议旨在就相关生物制品许可申请（BLA）进行关键讨论。\n在会议结束后，公司计划迅速行动，于2026年第三季度内重新提交该BLA申请。这一时间表凸显了公司推进其研发管线的决心与效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","RGNX","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154362997","title":"Regenxbio：与FDA就Naxsunli潜在加速批准所需后续步骤达成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1154362997","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154362997?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:40","pubTimestamp":1782128436,"startTime":"0","endTime":"0","summary":"Regenxbio公司表示，已与美国食品药品监督管理局（FDA）就基因疗法Naxsunli获得潜在加速批准所需的后续步骤达成共识。公司发言人指出，双方已明确后续行动方向，为推进该疗法的审评进程奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4563","RGNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126499596","title":"Regenxbio宣布与FDA就Navsunli™加速批准BLA重新提交路径达成一致；首款潜在MPS II基因疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1126499596","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126499596?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:31","pubTimestamp":1782127877,"startTime":"0","endTime":"0","summary":"Regenxbio公司近日宣布，已与美国食品药品监督管理局就Navsunli™生物制品许可申请的重新提交路径达成一致，旨在寻求加速批准。该疗法有望成为针对黏多糖贮积症II型的首款基因疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4505","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117785366","title":"消息称FDA将推翻罕见病药物否决决定，Regenxbio盘前股价飙升11.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117785366","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117785366?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:56","pubTimestamp":1782125808,"startTime":"0","endTime":"0","summary":"有报道称，美国食品药品监督管理局将撤销此前对Regenxbio公司罕见病治疗药物的否决决定。受此利好消息推动，Regenxbio股价在盘前交易时段应声大涨11.2%。\n这一戏剧性反转为这家生物技术公司带来了新的希望。市场情绪迅速转向乐观，投资者纷纷押注该药物最终有望获得监管批准。若消息属实，将标志着公司研发管线的重要突破。\n罕见病药物领域向来具有高风险、高回报的特性。监管态度的转变往往能瞬间重塑市场格局。本次股价的剧烈波动，正反映了投资者对监管风向变化的敏锐捕捉。\n目前，相关各方尚未对报道内容发表正式评论。但资本市场的热烈反应已清晰表明，市场预期正在发生根本性转变。后续进展值得密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4563","RGNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125600512","title":"Regenxbio公布关键性III期AFFINITY Duchenne®研究中RGX-202的积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1125600512","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125600512?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:01","pubTimestamp":1778756516,"startTime":"0","endTime":"0","summary":"生物技术公司Regenxbio Inc宣布，其针对杜氏肌营养不良症（DMD）的研究性基因疗法RGX-202，在关键性III期AFFINITY Duchenne®研究中取得了积极的顶线结果。\n数据显示，该疗法达到了研究的主要终点，在患者运动功能的关键评估指标上表现出具有统计学意义和临床意义的改善。安全性方面，RGX-202的耐受性普遍良好，观察到的不良事件与先前研究一致。\n这一积极结果为RGX-202的后续监管申请奠定了坚实基础。公司计划基于这些数据，与全球监管机构进行讨论，以推动该疗法早日惠及DMD患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4505","RGNX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195469481","title":"Regenxbio Inc 三期研究达到主要终点，93%患者微肌营养不良蛋白表达超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195469481","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195469481?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:01","pubTimestamp":1778756514,"startTime":"0","endTime":"0","summary":"Regenxbio公司宣布，其三期临床研究成功达到主要终点。数据显示，高达93%的受试患者体内微肌营养不良蛋白的表达水平超过了10%。这一关键成果标志着该公司在基因疗法领域取得了重要进展，为相关疾病的治疗带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","RGNX","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187547111","title":"Regenxbio公司RGX-202疗法显示微肌营养不良蛋白表达与功能改善显著相关","url":"https://stock-news.laohu8.com/highlight/detail?id=1187547111","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187547111?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:01","pubTimestamp":1778756494,"startTime":"0","endTime":"0","summary":"Regenxbio公司公布的最新数据显示，其基因疗法候选产品RGX-202在临床试验中展现出令人鼓舞的结果。研究证实，患者体内微肌营养不良蛋白的表达水平与其运动功能的临床改善之间存在显著的正相关性。\n这一发现为RGX-202治疗杜氏肌营养不良症的有效性提供了关键的科学依据，表明提升目标蛋白的表达可直接转化为患者获益。公司将继续推进该疗法的临床开发，以评估其长期安全性与疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4505","RGNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129931777","title":"Regenxbio Inc 将继续依据现有再授权协议向葛兰素史克支付从被再授权方获得的款项 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1129931777","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129931777?lang=zh_cn&edition=full","pubTime":"2026-03-21 05:20","pubTimestamp":1774041636,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件，生物技术公司Regenxbio Inc已确认，将继续依据其与制药巨头葛兰素史克之间现有的再授权协议，向后者支付从被再授权方处收到的相关款项。\n该安排明确了Regenxbio在相关知识产权商业化进程中的财务义务，确保了协议条款的持续履行。此举反映了双方长期合作关系的稳定性，以及对既定合约条款的遵守。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4139","LU0058720904.USD","LU0203347892.USD","IE00B3T34201.USD","SGXZ57979304.SGD","LU0971552830.HKD","IE00BQJZX424.USD","LU1400636491.USD","GSK.UK","LU0203345920.USD","LU1983299246.USD","LU1064927863.SGD","LU0321505868.SGD","BK4563","LU1228905037.USD","LU0289739699.SGD","LU0575583348.USD","LU1645745479.HKD","LU1309081286.SGD","SG9999001176.USD","LU0211331839.USD","LU0306806265.USD","LU1015430645.USD","LU0225284248.USD","LU0161305163.EUR","LU0545562505.USD","LU1098665638.USD","LU1228905540.USD","LU0109981661.USD","IE0034235071.USD","SG9999013999.USD","LU0971552673.USD","LU1670756490.USD","SG9999001176.SGD","LU1487256676.USD","LU1302929846.USD","LU1481599808.USD","LU0321505439.SGD","LU0985481810.HKD","LU1046248800.SGD","LU1400636574.HKD","IE00BWDBJ516.SGD","BK4505","BK5011","LU0306807586.USD","LU1202635105.USD","LU1481600234.SGD","LU1400636657.SGD","LU1035777561.USD","LU0225771236.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157978172","title":"Regenxbio Inc将向葛兰素史克支付1000万美元 以解决分许可费支付不足指控","url":"https://stock-news.laohu8.com/highlight/detail?id=1157978172","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157978172?lang=zh_cn&edition=full","pubTime":"2026-03-21 05:19","pubTimestamp":1774041550,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）的一份文件披露，生物技术公司Regenxbio Inc（RGNX）将向制药巨头葛兰素史克（GSK.UK）支付1000万美元，以了结后者关于其分许可费用支付不足的指控。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1046248800.SGD","LU1228905037.USD","LU0545562505.USD","LU0306806265.USD","BK4563","LU0225771236.USD","LU1481600234.SGD","LU1400636491.USD","LU1035777561.USD","LU1487256676.USD","LU1228905540.USD","RGNX","SG9999013999.USD","LU1202635105.USD","LU0161305163.EUR","IE0034235071.USD","LU1309081286.SGD","LU0321505868.SGD","LU1645745479.HKD","LU1302929846.USD","LU1400636657.SGD","IE00BWDBJ516.SGD","GSK.UK","LU0203347892.USD","LU0321505439.SGD","LU0306807586.USD","LU0971552830.HKD","SG9999001176.USD","LU0211331839.USD","LU0575583348.USD","LU0225284248.USD","LU1983299246.USD","SGXZ57979304.SGD","LU1064927863.SGD","LU0289739699.SGD","LU0985481810.HKD","LU0058720904.USD","LU0203345920.USD","SG9999001176.SGD","BK4505","BK4139","IE00BQJZX424.USD","LU1481599808.USD","LU1670756490.USD","LU0971552673.USD","LU1015430645.USD","LU1400636574.HKD","BK5011","LU0109981661.USD","LU1098665638.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162955575","title":"Regenxbio Inc与葛兰素史克达成和解与免责协议 日期锁定2026年3月18日——美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1162955575","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162955575?lang=zh_cn&edition=full","pubTime":"2026-03-21 05:18","pubTimestamp":1774041494,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新文件显示，生物技术公司Regenxbio Inc已与制药巨头葛兰素史克（GlaxoSmithKline）正式签署和解与免责协议。该协议于2026年3月18日生效，标志着双方就相关争议达成最终解决方案。\n此项协议的签署终止了双方此前存在的法律争议，为未来可能的合作清除了障碍。文件未披露具体和解金额及协议细节，但明确双方均同意免除彼此在此事上的所有追索权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","RGNX","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518618275","title":"Regenxbio Inc.盘中异动 大幅下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518618275","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518618275?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:43","pubTimestamp":1741617829,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时43分，Regenxbio Inc.股票出现波动，股价快速跳水5.05%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3488.18%、763.71%、655.35%，振幅较大的相关个股有Scisparc Ltd.、Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为45.06%、41.36%、40.33%。Regenxbio Inc.公司简介：Regenxbio Inc是一家生物技术公司。Regenxbio平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022434998a2aef9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022434998a2aef9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","BK4139","RGNX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517924359","title":"Regenxbio Inc.盘中异动 快速上涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517924359","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517924359?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:54","pubTimestamp":1741208046,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时54分，Regenxbio Inc.股票出现波动，股价大幅拉升5.15%。截至发稿，该股报6.23美元/股，成交量59.3174万股，换手率1.20%，振幅6.25%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为1.91%。Regenxbio Inc.公司简介：Regenxbio Inc是一家生物技术公司。Regenxbio平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045406a261314c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045406a261314c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","BK4563","RGNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516670723","title":"Regenxbio Inc.盘中异动 早盘股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516670723","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516670723?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:52","pubTimestamp":1741099954,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时52分，Regenxbio Inc.股票出现波动，股价急速跳水5.06%。截至发稿，该股报5.62美元/股，成交量11.8075万股，换手率0.24%，振幅3.38%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为0.32%。Regenxbio Inc.公司简介：Regenxbio Inc是一家生物技术公司。Regenxbio平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422523496394b43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422523496394b43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4563","RGNX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516446651","title":"Regenxbio Inc.盘中异动 下午盘急速跳水5.13%报6.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516446651","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516446651?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:05","pubTimestamp":1741025150,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时05分，Regenxbio Inc.股票出现波动，股价快速下挫5.13%。截至发稿，该股报6.23美元/股，成交量23.5561万股，换手率0.48%，振幅5.94%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为0.30%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Radiopharm Theranostics Limited涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4340.04%、182.86%、178.82%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Regenxbio Inc.公司简介：Regenxbio Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304020551a25d7e8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304020551a25d7e8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RGNX","BK4505","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514090499","title":"Regenxbio Inc.盘中异动 股价大跌5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090499","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514090499?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:35","pubTimestamp":1740494146,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时35分，Regenxbio Inc.股票出现波动，股价急速跳水5.34%。截至发稿，该股报6.56美元/股，成交量5.7193万股，换手率0.12%，振幅4.04%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为0.44%。其相关个股中，Moleculin Biotech, Inc.、Silexion Therapeutics Corp、Adial Pharmaceuticals, Inc涨幅较大，Gt Biopharma, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为773.84%、490.39%、259.00%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Gt Biopharma, Inc.、Moleculin Biotech, Inc.，振幅分别为20.51%、18.23%、15.89%。Regenxbio Inc.公司简介：Regenxbio Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223547a253882e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223547a253882e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","RGNX","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513720933","title":"Regenxbio Inc.盘中异动 股价大跌5.09%报6.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720933","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513720933?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:03","pubTimestamp":1740409435,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时03分，Regenxbio Inc.股票出现异动，股价急速跳水5.09%。截至发稿，该股报6.90美元/股，成交量10.7132万股，换手率0.22%，振幅4.37%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为0.34%。其相关个股中，Pepgen Inc.、Avalo Therapeutics, Inc.、Telix Pharmaceutic涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为158.08%、70.49%、25.66%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、42.86%。Regenxbio Inc.公司简介：Regenxbio Inc是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230355abdb15ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230355abdb15ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4563","BK4139","RGNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512165444","title":"Regenxbio Inc.盘中异动 大幅上涨5.07%报7.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165444","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512165444?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:42","pubTimestamp":1739889778,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时42分，Regenxbio Inc.股票出现波动，股价急速上涨5.07%。截至发稿，该股报7.67美元/股，成交量8.4641万股，换手率0.17%，振幅4.75%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为0.55%。Regenxbio Inc.公司简介：Regenxbio Inc是一家生物技术公司。Regenxbio平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224258a24aaf55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224258a24aaf55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4563","BK4505","RGNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511397691","title":"Regenxbio Inc.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511397691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511397691?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:47","pubTimestamp":1739544451,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时47分，Regenxbio Inc.股票出现异动，股价快速拉升5.05%。截至发稿，该股报7.69美元/股，成交量6.3388万股，换手率0.13%，振幅5.61%。Regenxbio Inc.股票所在的生物技术行业中，整体涨幅为0.23%。Regenxbio Inc.公司简介：Regenxbio Inc是一家生物技术公司。Regenxbio平台针对的疾病是代谢性疾病、神经退行性疾病和视网膜疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224731a24604f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224731a24604f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","RGNX","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regenxbio.com","stockEarnings":[{"period":"1week","weight":-0.0906},{"period":"1month","weight":-0.1622},{"period":"3month","weight":0.3901},{"period":"6month","weight":0.0187},{"period":"1year","weight":-0.1173},{"period":"ytd","weight":-0.3937}],"compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0138},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1512},{"period":"1year","weight":0.1723},{"period":"ytd","weight":0.118}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Regenxbio Inc.于2008年7月16日成立。该公司是一家领先的生物技术公司，专注于重组腺相关病毒基因疗法的开发、商业化和授权。在AAV基因疗法中，病毒基因从AAV（一种小型、非致病性感冒病毒）中移除，从而构建一种称为载体的生物递送工具。然后，将治疗性基因序列插入其中，形成重组载体。该公司拥有专有的AAV基因递送平台，该平台包含100多种新型AAV载体的独家使用权，其中包括AAV7、AAV8、AAV9和AAVrh10。公司的使命是基于其NAV技术平台，开发和商业化直接注射到体内（即体内给药）的基因治疗产品，从而改善患有严重疾病且存在重大未满足医疗需求的患者的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.091067},{"month":2,"riseRate":0.272727,"avgChangeRate":0.000501},{"month":3,"riseRate":0.545455,"avgChangeRate":0.007203},{"month":4,"riseRate":0.636364,"avgChangeRate":0.038941},{"month":5,"riseRate":0.272727,"avgChangeRate":-0.040299},{"month":6,"riseRate":0.636364,"avgChangeRate":0.107793},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.01896},{"month":8,"riseRate":0.363636,"avgChangeRate":0.01424},{"month":9,"riseRate":0.545455,"avgChangeRate":0.057459},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.060741},{"month":11,"riseRate":0.727273,"avgChangeRate":0.164969},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.05132}],"exchange":"NASDAQ","name":"Regenxbio Inc","nameEN":"Regenxbio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regenxbio Inc(RGNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Regenxbio Inc(RGNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Regenxbio Inc,RGNX,Regenxbio Inc股票,Regenxbio Inc股票老虎,Regenxbio Inc股票老虎国际,Regenxbio Inc行情,Regenxbio Inc股票行情,Regenxbio Inc股价,Regenxbio Inc股市,Regenxbio Inc股票价格,Regenxbio Inc股票交易,Regenxbio Inc股票购买,Regenxbio Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regenxbio Inc(RGNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Regenxbio Inc(RGNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}